🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 161 of 857 · Phase 3 first, then by program name

  1. Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®)

    Chiesi Farmaceutici S.p.A

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  2. Roflumilast 0.3% cream

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  3. Roflumilast Cream

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  4. Roflumilast Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  5. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    Atopic Dermatitis Eczema

    phase 3 small molecule completed

    1 trial

  6. Roflumilast Foam

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 3 small molecule completed

    1 trial

  7. Roflumilast Foam 0.3%

    Arcutis Biotherapeutics

    Scalp Psoriasis

    phase 3 small molecule completed

    1 trial

  8. Romiplostim

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  9. Ropeginterferon alfa-2b

    PharmaEssentia

    Primary Myelofibrosis

    phase 3 mab active

    1 trial

  10. Ropivacaine HCL

    Atrium Therapeutics

    Renal Carcinoma

    phase 3 small molecule active

    1 trial

  11. Ropivacaína Altan 2 mg/ml solución inyectable EFG, Adrenalina B. Braun 1 mg/ml Solución Inyectable

    The George Institute

    lumbar arthrodesis

    phase 3 small molecule active

    1 trial

  12. Rosiglitazone Extended Release 2mg

    GlaxoSmithKline

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial

  13. Rosuvastatin 20mg

    AstraZeneca

    Homozygous Familial Hypercholesterolemia (HoFH)

    phase 3 small molecule completed

    1 trial

  14. Rosuvastatin Placebo, MK-0616 (Enlicitide chloride) Placebo, MK-0616, ROSUVASTATIN

    Merck Sharp and Dohme

    Hyperlipidemia

    phase 3 small molecule active

    1 trial

  15. Roux-en-Y anastomosis

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  16. Roxadustat

    AstraZeneca

    Anemia

    phase 3 small molecule completed

    1 trial

  17. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Lacuna Pharma Pty Ltd

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  18. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Hoffmann-La Roche

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  19. Rucaparib

    pharmaand GmbH

    Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  20. Rukobia 600 mg prolonged-release tablets

    ViiV Healthcare Pty Ltd

    Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1

    phase 3 small molecule active

    1 trial

  21. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  22. Ruxolitinib

    Novartis Pharmaceuticals

    Polycythemia Vera

    phase 3 small molecule completed

    1 trial

  23. Ruxolitinib (INCB018424) cream, Ruxolitinib (INCB018424) cream, Vehicle (placebo) cream

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  24. Ruxolitinib (INCB018424) cream, Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid)

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources